NEW YORK – Myriad Genetics said Monday that it has inked an exclusive license deal with Pathomiq for the use of the Pathomiq_Prad artificial intelligence (AI)-enabled prostate cancer image analysis platform within the US.
The deal, the financial details of which were not disclosed, will allow Salt Lake City-based Myriad to support its Prolaris quantitative RT-PCR prostate cancer assay with Pathomiq_Prad's image-based technology for identifying high-risk prostate cancer patients likely to experience early metastasis following radical prostatectomy and for predicting treatment response.
Although Pathomiq_Prad is specific for post-surgery use in prostate cancer patients, its underlying model opens possible applications across all solid tumors diagnosed through biopsy and H&E staining. Myriad hopes that this will accelerate timelines for meeting Simon level one evidence — typically meaning evidence derived from a systematic review of all relevant randomized controlled clinical trials — for both Prolaris and Pathomiq_Prad.
"Along with our Prolaris Prostate Cancer Prognostic Test, we are pleased to leverage Pathomiq's prognostic and predictive capabilities across different phases of the patient journey in prostate cancer," George Daneker, president and chief clinical officer for oncology at Myriad, said in a statement. "Having both genetic and morphologic insights at the time of biopsy combined with the enhanced ability to predict disease recurrence after initial therapy can lead to more informed treatment decisions and enhance the potential for better patient outcomes. This partnership is the latest step in the strategic expansion of Myriad's oncology portfolio."